959705-18-1Relevant academic research and scientific papers
METHOD FOR PRODUCING OPTICALLY ACTIVE 2, 3-BISPHOSPHINOPYRAZINE DERIVATIVE AND METHOD FOR PRODUCING OPTICALLY ACTIVE PHOSPHINE TRANSITION METAL COMPLEX
-
, (2020/03/28)
In the method for producing an optically active 2,3-bisphosphinopyrazine derivative of the present invention, an optically active 2,3-bisphosphinopyrazine derivative represented by the following formula (3) is produced by the step of: preparing solution A containing 2,3-dihalogenopyrazine represented by the following formula (1) and a carboxylic acid amide coordinating solvent, lithiating an optically active R- or S-isomer of a hydrogen-phosphine borane compound represented by the following formula (2) to give a lithiated phosphine borane compound; adding solution B containing the lithiated phosphine borane compound to the solution A to perform an aromatic nucleophilic substitution reaction; and then performing a deboranation reaction. (For symbols in the formulas, see the description.)
METHOD FOR PRODUCING 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, AND METHOD FOR PRODUCING PHOSPHINE TRANSITION METAL COMPLEX
-
, (2020/08/20)
There is provided a method for producing a 2,3-bisphosphinopyrazine derivative, the method comprising a first step of adding a base to a liquid comprising: 2,3-dihalogenopyrazine represented by the following general formula (1); a hydrogen-phosphine borane compound represented by the following general formula (2); and a deboranating agent, and allowing the resultant to react to thereby obtain the 2,3-bisphosphinopyrazine derivative represented by the following general formula (3). According to the present invention, a method for producing the industrially advantageous 2,3-bisphosphinopyrazine derivative can be provided.
Efficient Preparation of (S)- and (R)- tert -Butylmethylphosphine-Borane: A Novel Entry to Important P-Stereogenic Ligands
Salomó, Ernest,Orgué, Sílvia,Riera, Antoni,Verdaguer, Xavier
, p. 2659 - 2663 (2016/08/11)
A novel one-pot reductive methodology for the synthesis of optically pure tert-butylmethylphosphine-borane is reported. The preparation uses as the starting material tert-butylmethylphosphinous acid-borane, which is available in both enantiomeric forms from cis-1,2-aminoindanol and tert-butyldichlorophosphine. The process is based on the reduction of a mixed anhydride, the configurational stability of which has been studied in several solvents and temperatures. Tetrabutylammonium borohydride was the best reducing agent allowing for the development of a practical process. To demonstrate the utility of the new methodology, the product obtained in this manner was used in the preparation of Quinox-P?.
Anticancer agent composition
-
, (2017/01/31)
Provided is an anti-cancer agent composition exhibiting excellent solubility and exerting high anti-cancer activity while exhibiting low toxicity. An anti-cancer composition characterized by containing a cyclodextrin compound and a phosphine transition metal complex represented by general formula (1). (In the formula, R1 and R2 represent a linear or branched alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a phenyl group having a substituent, have a carbon number between 1 and 10, and may represent the same group or different groups. R3 and R4 represent a hydrogen atom or a linear or branched alkyl group, have a carbon number between 1 and 6, and may represent the same group or different groups. R3 and R4 may form a saturated or unsaturated ring by bonding to one another and said saturated or unsaturated ring may have a substituent. M represents a transition metal atom selected from among gold, copper, and silver. X- represents an anion.)
ANTI-CANCER AGENT
-
Page/Page column 6, (2012/10/08)
The anti-cancer agent of the present invention contains at least one kind of phosphine transition metal complex selected from a group of compounds represented by the following Formulae (1a) to (1d). According to this anti-cancer agent, an anti-cancer agent is provided which has a higher anti-cancer activity and lower toxicity compared to anti-cancer agents in the related art. In Formulae (1a), (1b), (1c), and (1d), R1 and R2 represent a linear or branched alkyl group, and R4 has a higher priority than R2 as ranked according to RS notation. R3 and R4 represent a hydrogen atom or a linear or branched alkyl group. M represents an atom of a transition metal selected from a group consisting of gold, copper, and silver. X? represents an anion.
Rigid P-chiral phosphine ligands with tert -butylmethylphosphino groups for rhodium-catalyzed asymmetric hydrogenation of functionalized alkenes
Imamoto, Tsuneo,Tamura, Ken,Zhang, Zhenfeng,Horiuchi, Yumi,Sugiya, Masashi,Yoshida, Kazuhiro,Yanagisawa, Akira,Gridnev, Ilya D.
scheme or table, p. 1754 - 1769 (2012/03/11)
Both enantiomers of 2,3-bis(tert-butylmethylphosphino)quinoxaline (QuinoxP*), 1,2-bis(tert-butylmethylphosphino)benzene (BenzP*), and 1,2-bis(tert-butylmethylphosphino)-4,5-(methylenedioxy)benzene (DioxyBenzP*) were prepared in short steps from enantiopure (S)- and (R)-tert-butylmethylphosphine-boranes as the key intermediates. All of these ligands were crystalline solids and were not readily oxidized on exposure to air. Their rhodium complexes exhibited excellent enantioselectivities and high catalytic activities in the asymmetric hydrogenation of functionalized alkenes, such as dehydroamino acid derivatives and enamides. The practical utility of these catalysts was demonstrated by the efficient preparation of several chiral pharmaceutical ingredients having an amino acid or a secondary amine component. A rhodium complex of the structurally simple ligand BenzP* was used for the mechanistic study of asymmetric hydrogenation. Low-temperature NMR studies together with DFT calculations using methyl α-acetamidocinnamate as the standard model substrate revealed new aspects of the reaction pathways and the enantioselection mechanism.
PHOSPHINE TRANSITION METAL COMPLEX, METHOD FOR PRODUCING THE SAME AND ANTITUMOR AGENT
-
Page/Page column 8-9, (2009/04/23)
An anticancer agent having a novel chemical structure and high anticancer activity is provided. A phosphine transition metal complex of general formula (1) and an anticancer agent containing the complex are disclosed. R1 and R2, which may be the same or different, each represent a group having 1 to 10 carbon atoms selected from a straight-chain or branched alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an adamantyl group, a phenyl group, and a substituted phenyl group; R3 and R4, which may be the same or different, each represent a hydrogen atom, a straight-chain alkyl group having 1 to 6 carbon atoms or branched alkyl group having 1 to 6 carbon atoms; or R3 and R4 are taken together to form a saturated or unsaturated ring which may have a substituted group; M represents a transition metal atom selected from the group consisting of gold, copper, and silver; and X- represents an anion.
2, 3-Bis(dialkylphosphino)pyrazine derivative, process of producing the same, and metal complex having the same as ligand
-
Page/Page column 4, (2008/06/13)
An optically active 2,3-bis(dialkylphosphino)pyrazine derivative represented by formula (1) is disclosed. The pyrazine derivative is preferably a quinoxaline derivative represented by formula (2). In formula (1) and (2), R1 is preferably a t-butyl or adamantyl group, and R2 is preferably a methyl group. wherein R1 is a substituted or unsubstituted, straight chain or branched alkyl group having 2 to 10 carbon atoms; R2 is a substituted or unsubstituted, straight chain or branched alkyl group having fewer carbon atoms than R1; and R3 and R4, which may be the same or different, are each a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, or R3 and R4 are taken together to form a saturated or unsaturated ring. wherein R1 and R2 are as defined above; and R5 is a monovalent substituent.
An air-stable P-chiral phosphine ligand for highly enantioselective transition-metal-catalyzed reactions
Imamoto, Tsuneo,Sugita, Keitaro,Yoshida, Kazuhiro
, p. 11934 - 11935 (2007/10/03)
A new P-chiral phosphine ligand, (R,R)-2,3-bis(tert-butylmethylphosphino)quinoxaline, has been prepared by the reaction of enantiomerically pure tert-butylmethylphosphine-borane with 2,3-dichloroquinoxaline. This ligand, in contrast to most of the previously reported P-chiral ligands, is an air-stable solid and exhibits excellent enantioselectivities in both Rh-catalyzed asymmetric hydrogenations and Rh- or Pd-catalyzed carbon-carbon bond-forming reactions. Copyright
